Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou

Fabienne Marie Soudre; Arnaud Kouraogo; Abdou Nombre; Issa Tonde; Ollo Da; Thierry Etienne Kafando; Asciel Laël Ouedraogo; Delwende Job Tenkodogo; Alice Kiba; Raoul Karfo; Elie Kabre; Jean Sakande

doi:doi:10.11648/j.ab.20241201.14

Research Article |

Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou

Fabienne Marie Soudre^*, Arnaud Kouraogo, Abdou Nombre, Issa Tonde, Ollo Da, Thierry Etienne Kafando, Asciel Laël Ouedraogo, Delwende Job Tenkodogo, Alice Kiba, Raoul Karfo, Elie Kabre, Jean Sakande

Published in Advances in Biochemistry (Volume 12, Issue 1)

Received: 7 February 2024 Accepted: 29 February 2024 Published: 13 March 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte count > 500/mm³ and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p<0.00001), in patients with a high PVL (p=0.0016) and in those on the protocol combining two nucleoside reverse transcriptase inhibitors with a protease inhibitor. Several abnormalities in serum amylase activity were detected in CLHIV-1 during the course of the study. Clinical correlation and adequate follow-up of these abnormalities are essential to reduce the morbidity and mortality associated with pancreatic damage in people living with HIV.

Published in	Advances in Biochemistry (Volume 12, Issue 1)
DOI	10.11648/j.ab.20241201.14
Page(s)	29-34
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Hyperamylasemia, Serum Amylase Activity, Children, HIV-1, Burkina Faso

References

[1]	ONUSIDA. Global HIV & AIDS statistics — Fact sheet [Internet]. [cited 2023 Oct 22]. Available from: https://www.unaids.org/en/resources/fact-sheet
[2]	Organisation mondiale de la santé. Rapport annuel 2022 OMS Burkina Faso [Internet]. Burkina Faso; [cited 2023 Oct 22] p. 86. Available from: https://www.afro.who.int/sites/default/files/2023-08/Rapport%20annuel%202022_OMS%20Burkina%20Faso_Final_1.pdf
[3]	Boutitie F, Pocock SJ. Predictive value of repeated measurements of CD4 lymphocyte counts on progression to AIDS. AIDS Lond Engl. 1994 Jan; 8(1): 35–41. https://doi.org/ 10.1097/00002030-199401000-00006
[4]	Lamoril J, Bogard M. La quantification en biologie moléculaire: application à l’étude de la charge virale du virus VIH-1. Immuno-Anal Biol Spéc. 1996 Jan 1; 11(5): 325–32.
[5]	Yeni P. Prise en charge médicale des personnes infectées par le VIH: rapport 2010—Recommandations du groupe d’experts. Flammarion Médecine-Sciences. Paris, France; 2008. 412 p.
[6]	Brivet FG, Naveau SH, Lemaigre GF, Dormont J. Pancreatic lesions in HIV-infected patients. Baillières Clin Endocrinol Metab. 1994; 8(4): 859–77. https://doi.org/10.1016/S0950-351X(05)80306-4
[7]	Cappell MS. The pancreas in AIDS. Gastroenterol Clin North Am. 1997; 26(2): 337–65. https://doi.org/10.1016/S0889-8553(05)70298-3
[8]	Ilboudo B. L’amylasémie au cours de l’infection à VIH [Internet] [Thèse de doctorat en médecine]. [Ouagadougou, Burkina Faso]: Universite de Ouagadougou; 1973 [cited 2023 Oct 26]. Available from: https://beep.ird.fr/collect/uouaga/index/assoc/M09682.dir/M09682.pdf
[9]	Sagna Y, Koulidiaty J, Diallo I, Sanou AF, Bagbila PA, Sagna T, et al. Profil biologique des patients nouvellement pris en charge pour une infection à VIH à Ouagadougou (Burkina Faso). Médecine Santé Trop. 2014; 24(3): 307–11. https://www.jle.com/10.1684/mst.2014.0381
[10]	Smith RC, Southwell-Keely J, Chesher D. Should Serum Pancreatic Lipase Replace Serum Amylase as a Biomarker of Acute Pancreatitis? ANZ J Surg. 2005; 75(6): 399–404. https://doi.org/ 10.1111/j.1445-2197.2005.03391.x
[11]	Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem. 2017 Dec 1; 50(18): 1275–80. https://doi.org/10.1016/j.clinbiochem.2017.07.003
[12]	Lévy P. Amylases et lipases. Hépato-Gastro Oncol Dig. 2013; 20(8): 650–5. https://doi.org/10.1684/hpg.2013.0918
[13]	Murthy UK, DeGregorio F, Oates RP, Blair DC. Hyperamylasemia in patients with the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992; 87(3): 332–6.
[14]	Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, Chilongola J. The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci. 2012 Mar; 12(1): 2–7.
[15]	Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 1999. 2005 Sep 1; 40(1): 65–9. https://doi.org/10.1097/01.qai.0000159516.39982.1b
[16]	Nadembèga Christelle WM. Depistage anonyme du VIH, etude de l’evolution des proteines serique et des C+ chez les personnes vivant avec le VIH/SIDA. 2001; 45.
[17]	Jin Y, Yang T, Xia T, Shen Z, Ma T. Association between serum amylase levels and CD4 cell counts in newly diagnosed people living with HIV: A case-control study. Medicine (Baltimore). 2023 Jan 13; 102(2): e32638. https://doi.org/10.1097/MD.0000000000032638

Cite This Article

Plain Text BibTeX RIS

APA Style

Soudre, F. M., Kouraogo, A., Nombre, A., Tonde, I., Da, O., et al. (2024). Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Advances in Biochemistry, 12(1), 29-34. https://doi.org/10.11648/j.ab.20241201.14

Copy | Download

ACS Style

Soudre, F. M.; Kouraogo, A.; Nombre, A.; Tonde, I.; Da, O., et al. Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Adv. Biochem. 2024, 12(1), 29-34. doi: 10.11648/j.ab.20241201.14

Copy | Download

AMA Style

Soudre FM, Kouraogo A, Nombre A, Tonde I, Da O, et al. Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Adv Biochem. 2024;12(1):29-34. doi: 10.11648/j.ab.20241201.14

Copy | Download

@article{10.11648/j.ab.20241201.14,
  author = {Fabienne Marie Soudre and Arnaud Kouraogo and Abdou Nombre and Issa Tonde and Ollo Da and Thierry Etienne Kafando and Asciel Laël Ouedraogo and Delwende Job Tenkodogo and Alice Kiba and Raoul Karfo and Elie Kabre and Jean Sakande},
  title = {Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou},
  journal = {Advances in Biochemistry},
  volume = {12},
  number = {1},
  pages = {29-34},
  doi = {10.11648/j.ab.20241201.14},
  url = {https://doi.org/10.11648/j.ab.20241201.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20241201.14},
  abstract = {Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte count > 500/mm3 and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p), in patients with a high PVL (p=0.0016) and in those on the protocol combining two nucleoside reverse transcriptase inhibitors with a protease inhibitor. Several abnormalities in serum amylase activity were detected in CLHIV-1 during the course of the study. Clinical correlation and adequate follow-up of these abnormalities are essential to reduce the morbidity and mortality associated with pancreatic damage in people living with HIV.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou
AU  - Fabienne Marie Soudre
AU  - Arnaud Kouraogo
AU  - Abdou Nombre
AU  - Issa Tonde
AU  - Ollo Da
AU  - Thierry Etienne Kafando
AU  - Asciel Laël Ouedraogo
AU  - Delwende Job Tenkodogo
AU  - Alice Kiba
AU  - Raoul Karfo
AU  - Elie Kabre
AU  - Jean Sakande
Y1  - 2024/03/13
PY  - 2024
N1  - https://doi.org/10.11648/j.ab.20241201.14
DO  - 10.11648/j.ab.20241201.14
T2  - Advances in Biochemistry
JF  - Advances in Biochemistry
JO  - Advances in Biochemistry
SP  - 29
EP  - 34
PB  - Science Publishing Group
SN  - 2329-0862
UR  - https://doi.org/10.11648/j.ab.20241201.14
AB  - Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte count > 500/mm3 and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p), in patients with a high PVL (p=0.0016) and in those on the protocol combining two nucleoside reverse transcriptase inhibitors with a protease inhibitor. Several abnormalities in serum amylase activity were detected in CLHIV-1 during the course of the study. Clinical correlation and adequate follow-up of these abnormalities are essential to reduce the morbidity and mortality associated with pancreatic damage in people living with HIV.

VL  - 12
IS  - 1
ER  -

Copy | Download

Author Information

Fabienne Marie Soudre

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso; Laboratory Service, Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso

Contact Email
Arnaud Kouraogo

Biochemistry Unit, Sourou Sanou University Hospital, Bobo Dioulasso, Burkina Faso; Health Sciences Institute, Nazi BONI University, Bobo Dioulasso, Burkina Faso
Abdou Nombre

Laboratory Service, Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso
Issa Tonde

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso; Laboratory Service, Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso
Ollo Da

Biochemistry Unit, Sourou Sanou University Hospital, Bobo Dioulasso, Burkina Faso; Health Sciences Institute, Nazi BONI University, Bobo Dioulasso, Burkina Faso
Thierry Etienne Kafando

Health Sciences Faculty, Saint Thomas d'Aquin University, Ouagadougou, Burkina Faso
Asciel Laël Ouedraogo

Health Sciences Faculty, Saint Thomas d'Aquin University, Ouagadougou, Burkina Faso
Delwende Job Tenkodogo

Health Sciences Faculty, Saint Thomas d'Aquin University, Ouagadougou, Burkina Faso
Alice Kiba

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso; Laboratory Service, Tengandogo University Hospital, Ouagadougou, Burkina Faso
Raoul Karfo

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso
Elie Kabre

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso; National Agency for Environmental, Food, Labor and Health Product Safety, Ouagadougou, Burkina Faso
Jean Sakande

Health Sciences Training and Research Unit, Joseph Ki-Zerbo University, Ouagadougou, Burkina Faso; Biochemistry Service, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Soudre, F. M., Kouraogo, A., Nombre, A., Tonde, I., Da, O., et al. (2024). Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Advances in Biochemistry, 12(1), 29-34. https://doi.org/10.11648/j.ab.20241201.14

Copy | Download

ACS Style

Soudre, F. M.; Kouraogo, A.; Nombre, A.; Tonde, I.; Da, O., et al. Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Adv. Biochem. 2024, 12(1), 29-34. doi: 10.11648/j.ab.20241201.14

Copy | Download

AMA Style

Soudre FM, Kouraogo A, Nombre A, Tonde I, Da O, et al. Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou. Adv Biochem. 2024;12(1):29-34. doi: 10.11648/j.ab.20241201.14

Copy | Download

@article{10.11648/j.ab.20241201.14,
  author = {Fabienne Marie Soudre and Arnaud Kouraogo and Abdou Nombre and Issa Tonde and Ollo Da and Thierry Etienne Kafando and Asciel Laël Ouedraogo and Delwende Job Tenkodogo and Alice Kiba and Raoul Karfo and Elie Kabre and Jean Sakande},
  title = {Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou},
  journal = {Advances in Biochemistry},
  volume = {12},
  number = {1},
  pages = {29-34},
  doi = {10.11648/j.ab.20241201.14},
  url = {https://doi.org/10.11648/j.ab.20241201.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20241201.14},
  abstract = {Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte count > 500/mm3 and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p), in patients with a high PVL (p=0.0016) and in those on the protocol combining two nucleoside reverse transcriptase inhibitors with a protease inhibitor. Several abnormalities in serum amylase activity were detected in CLHIV-1 during the course of the study. Clinical correlation and adequate follow-up of these abnormalities are essential to reduce the morbidity and mortality associated with pancreatic damage in people living with HIV.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Serum Amylase Activity in Children Living with HIV-1 at the Charles de Gaulle Pediatric University Hospital in Ouagadougou
AU  - Fabienne Marie Soudre
AU  - Arnaud Kouraogo
AU  - Abdou Nombre
AU  - Issa Tonde
AU  - Ollo Da
AU  - Thierry Etienne Kafando
AU  - Asciel Laël Ouedraogo
AU  - Delwende Job Tenkodogo
AU  - Alice Kiba
AU  - Raoul Karfo
AU  - Elie Kabre
AU  - Jean Sakande
Y1  - 2024/03/13
PY  - 2024
N1  - https://doi.org/10.11648/j.ab.20241201.14
DO  - 10.11648/j.ab.20241201.14
T2  - Advances in Biochemistry
JF  - Advances in Biochemistry
JO  - Advances in Biochemistry
SP  - 29
EP  - 34
PB  - Science Publishing Group
SN  - 2329-0862
UR  - https://doi.org/10.11648/j.ab.20241201.14
AB  - Biological monitoring is an essential part of the management of HIV infection. The aim of this study was to assess serum amylase activity during follow-up of children living with HIV-1 (CLHIV-1) at the Charles de Gaulle Pediatric University Hospital (CHUP-CDG). This was a descriptive and analytical cross-sectional study, with retrospective data collection from January 1, 2020 to December 31, 2022. Patients under 15 years of age who were being monitored for HIV-1 at CHUP-CDG and who had undergone a serum amylase assay during the study period were included. A total of 746 patients have been included, with a M/F sex ratio of 0.91 and a mean age of 8.52±4.08 years. Among CLHIV-1, 88.05% had a TCD4 lymphocyte count > 500/mm3 and 60.32% an undetectable plasma viral load (PVL). The incidence of hyperamylasemia in the study population was 57.64%. Hyperamylasemia was significantly more frequent in children aged 0-2 years (p), in patients with a high PVL (p=0.0016) and in those on the protocol combining two nucleoside reverse transcriptase inhibitors with a protease inhibitor. Several abnormalities in serum amylase activity were detected in CLHIV-1 during the course of the study. Clinical correlation and adequate follow-up of these abnormalities are essential to reduce the morbidity and mortality associated with pancreatic damage in people living with HIV.

VL  - 12
IS  - 1
ER  -

Copy | Download